Julie McHugh
Director
Julie McHugh is a Director and a member of the Audit Committee. Ms. McHugh brings over 30 years of experience in the pharmaceutical, biotech and medical device industries.
She recently served as Chief Operating Officer of Endo Health Solutions, Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to that, Ms. McHugh was CEO of Nora Therapeutics, Inc., a venture capital-backed biotech startup company focused on developing novel therapies for the treatment of infertility disorders. Previously, she served as Company Group Chairman for Johnson & Johnson’s worldwide virology business unit, and before that, she was President of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine).
Prior to joining Centocor, Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves on the Board of Directors of Evelo Biosciences, Inc., Ironwood Pharmaceuticals, Inc. and New Xellia Group A/S. She previously served on the Boards of Directors of the Biotechnology Industry Organization, the New England Healthcare Institute, the Pennsylvania Biotechnology Association, Aerie Pharmaceuticals, Inc., EPIRUS Pharmaceuticals, Inc., Trevena Pharmaceuticals, Inc. and ViroPharma Inc.
Ms. McHugh received a Master of Business Administration from St. Joseph’s University and a Bachelor of Science from Pennsylvania State University.
